Literature DB >> 7584854

Immunosuppressive activity of angiogenin in comparison with bovine seminal ribonuclease and pancreatic ribonuclease.

J Matousek1, J Soucek, J Ríha, T R Zankel, S A Benner.   

Abstract

Angiogenin, a member of the pancreatic-like ribonuclease family with a special biological action (RISBAses), is a basic protein that induces blood vessel formation. Another member of these special ribonucleases, bovine seminal ribonuclease (BS RNase), displays biological properties, including aspermatogenic, embryotoxic, antitumor and immunosuppressive activities. The effects of two angiogenin preparations tested on the biological activities mentioned above are reported and compared with those of BS RNase and RNase A. In contrast to RNase A, which was ineffective in all biological activities tested, angiogenin suppressed significantly the proliferation of human lymphocytes stimulated by phytohemagglutinin or concanavalin A or by allogenic human lymphocytes (mixed lymphocyte culture). However, angiogenin did not affect the growth of human tumor cell lines, development of cow and mouse embryos and spermatogenicity in mice. On the basis of these results, angiogenin is the first monomeric ribonuclease described so far that displays immunosuppressive activity similar to that of the dimeric BS RNase. The immunosuppressive activity of angiogenin might synergize with the effect on neovascularization of tumor tissues and thus contribute to the development of tumor.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7584854     DOI: 10.1016/0305-0491(95)00075-5

Source DB:  PubMed          Journal:  Comp Biochem Physiol B Biochem Mol Biol        ISSN: 1096-4959            Impact factor:   2.231


  12 in total

1.  Mechanism and Function of Angiogenin in Hematopoietic Malignancy.

Authors:  Kevin A Goncalves; Guo-Fu Hu
Journal:  Zhongguo Sheng Wu Hua Xue Yu Fen Zi Sheng Wu Xue Bao       Date:  2015-12-23

2.  A novel ribonuclease with potent HIV-1 reverse transcriptase inhibitory activity from cultured mushroom Schizophyllum commune.

Authors:  Yong-Chang Zhao; Guo-Qing Zhang; Tzi-Bun Ng; He-Xiang Wang
Journal:  J Microbiol       Date:  2011-11-09       Impact factor: 3.422

Review 3.  Ribonuclease inhibitor: structure and function.

Authors:  Kimberly A Dickson; Marcia C Haigis; Ronald T Raines
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2005

4.  Serum angiogenin in inflammatory bowel disease.

Authors:  Ioannis E Koutroubakis; Costas Xidakis; Konstantinos Karmiris; Aekaterini Sfiridaki; Ermioni Kandidaki; Elias A Kouroumalis
Journal:  Dig Dis Sci       Date:  2004 Nov-Dec       Impact factor: 3.199

5.  Ribonucleases endowed with specific toxicity for spermatogenic layers.

Authors:  Josef Matoušek; Jin-Soo Kim; Josef Souček; Jan Rìha; Marc Ribó; Peter A Leland; Ronald T Raines
Journal:  Comp Biochem Physiol B Biochem Mol Biol       Date:  1997-12       Impact factor: 2.231

Review 6.  Three decades of research on angiogenin: a review and perspective.

Authors:  Jinghao Sheng; Zhengping Xu
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2015-12-23       Impact factor: 3.848

7.  Elevated angiogenin levels in synovial fluid from patients with inflammatory arthritis and secretion of angiogenin by cultured synovial fibroblasts.

Authors:  F Lioté; R Champy; M Moenner; B Boval-Boizard; J Badet
Journal:  Clin Exp Immunol       Date:  2003-04       Impact factor: 4.330

8.  Angiogenin distribution in human term placenta, and expression by cultured trophoblastic cells.

Authors:  Nadine Pavlov; Elissavet Hatzi; Yann Bassaglia; Jean-Louis Frendo; Danièle Evain Brion; Josette Badet
Journal:  Angiogenesis       Date:  2003       Impact factor: 9.596

9.  First biochemical characterization of a novel ribonuclease from wild mushroom Amanita hemibapha.

Authors:  Malota Sekete; Duanzheng Ma; Bo Wang; Hexiang Wang; Tzibun Ng
Journal:  Springerplus       Date:  2012-12-27

10.  Design, characterization and anti-tumour cytotoxicity of a panel of recombinant, mammalian ribonuclease-based immunotoxins.

Authors:  M P Deonarain; A A Epenetos
Journal:  Br J Cancer       Date:  1998-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.